A phase 3 trial of semagacestat for treatment of Alzheimer's disease

New England Journal of Medicine

Volumn 369, Issue 4, 2013, Pages 341-350

  Doody, Rachelle S ^a   Raman, Rema ^b,c   Farlow, Martin ⁱ   Iwatsubo, Takeshi ^d   Vellas, Bruno ^e   Joffe, Steven ^f   Kieburtz, Karl ^g   He, Feng ^b   Sun, Xiaoying ^b   Thomas, Ronald G ^b,c   Aisen, Paul S ^c   Siemers, Eric ^h   Sethuraman, Gopalan ^h   Mohs, Richard ^h  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TOKYO   (Japan)

^e Serv Univ Psychiat l'Enfant l'A   (France)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^h ELI LILLY AND COMPANY   (United States)

ⁱ INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CHOLINESTERASE INHIBITOR; DONEPEZIL; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; MEMANTINE; PLACEBO; SEMAGACESTAT; TAU PROTEIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ALZHEIMER DISEASE COOPERATIVE STUDY ACTIVITIES OF DAILY LIVING SCALE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BASAL CELL CARCINOMA; BRAIN SIZE; CLINICAL DEMENTIA RATING SUM OF BOXES; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DECREASED APPETITE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG WITHDRAWAL; ENTORHINAL CORTEX; EOSINOPHIL COUNT; EPISTAXIS; ERYTHEMA; EYELASH DISCOLORATION; FAINTNESS; FANCONI RENOTUBULAR SYNDROME; FEMALE; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; HAIR COLOR; HAIR DISCOLORATION; HIPPOCAMPUS; HUMAN; HYPOPIGMENTATION; INFECTION; LIVER CELL DAMAGE; LYMPHOCYTE COUNT; MACULAR RASH; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MONOCYTE; NAUSEA; NEUROIMAGING; NEUROPSYCHIATRIC INVENTORY; NON MELANOMA SKIN CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PAPULAR RASH; PHASE 3 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PRURITUS; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; SKIN CANCER; SKIN CARCINOMA; URIC ACID BLOOD LEVEL; URINE ACIDIFICATION; VOMITING; WEIGHT REDUCTION;

EID: 84880712325     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1210951     Document Type: Article

References (24)

1. Jack C, Berezovska O, Wolfe MS, Hyman BT. Effect of PS1 deficiency and an APP gamma-secretase inhibitor on Notch1 signaling in primary mammalian neurons. Brain Res Mol Brain Res 2001;87: 166-74. (Pubitemid 32195467)
2. Geling A, Steiner H, Willem M, Bally-Cuif L, Haass C. A gamma-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish. EMBO Rep 2002;3:688-94.
3. Micchelli CA, Esler WP, Kimberly WT, et al. Gamma-secretase/presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations in Drosophila. FASEB J 2003;17:79-81.
4. Wong GT, Manfra D, Poulet FM, et al. Chronic treatment with gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004;279:12876-82. (Pubitemid 38445862)
5. May PC, Yang Z, Li W-Y, Hyslop PA, Siemers E, Boggs LN. Multi-compartmental pharmacodynamic assessment of the functional gamma-secretase inhibitor LY450139 dihydrate in PDAPP transgenic mice and non-transgenic mice. Neurobiol Aging 2004;25:Suppl 2:S65.
6. Evin G, Semee MF, Masters CL. Inhibition of γ-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies. CNS Drugs 2006;20:351-72. (Pubitemid 43763737)
7. Siemers ER, Quinn JF, Kaye J, et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer's disease. Neurology 2006;66: 602-4. (Pubitemid 43739900)
8. Bateman RJ, Siemers ER, Mawuenyega KG, et al. A γ-secretase inhibitor decreases amyloid-β production in the central nervous system. Ann Neurol 2009;66:48-54.
9. Gitter BD, Czilli DL, Li W, et al. Stereoselective inhibition of amyloid beta peptide secretion by LY450139, a novel functional gamma-secretase inhibitor. Neurobiol Aging 2004;25:Suppl 2:S571.
10. Siemers E, Skinner M, Dean RA, et al. Safety, tolerability and changes in amyloid beta concentrations after administrations of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol 2005;28: 126-32. (Pubitemid 40923411)
11. Fleisher AS, Raman R, Siemers ER, et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 2008;65:1031-8.
12. Sheikh JL, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development of the shorter version. In: Brink TL, ed. Clinical gerontology: a guide to assessment and intervention. New York: Haworth Press, 1986:165-74.
13. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12: 189-98.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34:939-44. (Pubitemid 14076461)
15. Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. Alzheimer Dis Assoc Disord 1997;11:Suppl 2:S13-S21.
16. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord 1997; 11:Suppl 2:S33-S39.
17. Berg L, Miller JP, Baty J, Rubin EH, Morris JC, Figiel G. Mild senile dementia of the Alzheimer's type: 4. Evaluation of intervention. Ann Neurol 1992;31:242-9.
18. O'Bryant SE, Waring SC, Cullum CM, et al. Staging dementia using Clinical Dementia Rating Scale Sum of Box scores: a Texas Alzheimer's Research Consortium study. Arch Neurol 2008;65:1091-5.
19. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44: 2308-14. (Pubitemid 24382728)
20. Wimo A, Wetterholm A-L, Mastey V, Winbald B. Evaluation of the healthcare resource utilization and caregiver time in anti-dementia drug trials. In: Wimo A, Jönsson B, Karlsson G, Winblad B, eds. The health economics of dementia. London: Wiley, 1998:465-99.
21. Kind P. The EuroQol instrument: an index of health-related quality of life. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:191-201.
22. Wallace JI, Schwartz RS, LaCroix AZ, Uhlmann RF, Pearlman RA. Involuntary weight loss in older outpatients: incidence and clinical significance. J Am Geriatr Soc 1995;43:329-37.
23. Chávez-Gutiérrez L, Bammens L, Benilova I, et al. The mechanism of γ-secretase dysfunction in familial Alzheimer disease. EMBO J 2012;31:2261-74.
24. Roher AE, Esh CL, Kokjohn TA, et al. Aβ peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement 2009;5:18-29.